Presenter's Information
Roxana Mehran, MD
Country | USA |
Specialty | Interventional Cardiologist |
- Next Novel Antithrombotic Drugs for ACS/PCI: Oral Factor XIa inhibitor or More
- Year-In-Review: Interventional Pharmacology
- Optimal DAPT Duration for PCI Patients at High Beeding Risk
- Potent P2Y12 Inhibitors for East-Asian Patients: Insights from the TWIGHLIGHT in Western vs. Asian Population
- Interventional Pharmacology Year-In-Review
- Aspirin Plus NOAC Will Be the Standard of Care.
- HARMONEE: A Randomized Trial of a Bioabsorbable Polymer-based DES with a Luminal CD34+ Antibody Coating Versus a Durable Polymer-based DES in Patients with Coronary Artery Disease
- Optimal Balancing Ischemic and Bleeding Risks in Contemporary PCI Practice: TWILIGHT, GLOBAL-LEADER and More...
- Optimal Initiation and Duration of DAPT in ACS Patient; Reviewing the Evidence of Ticagrelor
- Pretreatment with P2Y12 Inhibitors in NSTE-ACS: Selective vs. Routine?
- EPC Capture Stent : A Promising Solution Amongst the DAPT Controversy?
- The DAPT Debate - 2016
- Upcoming Trend in ACS Patient Management
- The DAPT Duration Debate - Practical Synthesis and Clinical Recommendations
- Vulnerable Plaque Is a Systemic Disease: Insights from BioImage
- Revisiting Anticoagulants: Why Dual Pathway Inhibition Is Not Back?
- Optimal DAPT Duration for Current and Future DES and BVS
- Will Long Term Dual Antiplatelet Therapy Improve LT Outcome?
- Does True Vessel Healing Matter?
- Interventional Pharmacology - Year in Review
- No Benefits, Possible Harms - The ACCOAST Trial
- The Next Era: COMBO Dual Therapy Stent
- [Bivalirudin: Is It Standard of Care in the Cath Lab?] No, Heparin with Provisional GPI Is Still a Viable Option.
- Surveying the Landscape of New Anti-platelet Agents: A Practical User¡¯s Guide
- Update on Left Main/Multivessel PCI: Lessons from SYNTAX, a View to EXCEL
- Impact of Bleeding and Tailored or Personalized Antiplatlet Therapy to Reduce Bleeding in ACS or PCI Patients: From Clopidogrel to Prasugrel and Ticagrelor
- Bleeding & Mortality: Beyond the Horizon
- The NEW Anti-platelet Agents and Platelet Reactivity Testing: Recommendations for Prasugrel and Ticagrelor and Lessons from GRAVATAS
- Behind Closed Doors: Functions of a Data Safety Monitoring Board
- Types of Clinical Trials in Cardiology: The Rationale for Trial Design
- PCI in Chronic Kidney Disease (RECOVER, CARE, LOCM-Related Studies, and Meta-Analysis)
- Parenteral Anticoagulants Use in ACS (HORIZONS-AMI, and SEPIA-ACS Trial)
- The Role of New Anti-platelet Agents: Will Prasugrel and Ticagrelor Change the DES Landscape?
- Anti-Platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib
- New Paradigms in Treatment of ACS/AMI
- Quality Control of Clinical Trials: Blinding, Clinical Event Committees, Core Labs, and Data Standards
- ACS/AMI: What¡¯s Hot, What¡¯s Not!
- Impact of Ischemic vs. Bleeding Endpoints: Lessons from ACUITY and HORIZONS
- The Impact of Hemorrhagic Complications on PCI Outcomes: Lessons from ACUITY, HORIZONS and Other Trials
- TRITON - TIMI 38: The Future Role of Prasugrel (and Other New Anti-Platelet Agents) in PCI
- In-Stent Restenosis
- HORIZONS AMI: Bivalirudin vs. Unfractionated Heparin plus GPIIb/IIIa Inhibitors in STEMI
- The Interventional Trials of the Year: 2007-2008 (TCT, AHA, and ACC)
- The CoStar Clinical Data
- ACUITY: One Year Outcome of ACUITY Trial
- Renal Failure and Contrast Nephropathy: An Overview and Considerations in the PCI Patient
- The Interventional Trials of the Year: 2006-2007 (TCT, AHA, and ACC)
- Complications Related to the Use of Radiocontrast Agents
- A Prospective "All Comers" CYPHER Nonrandomized Registry in Complex Patients From MATRIX
- Revised Protocol of COMBAT(Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease)
- Radiocontrast Nephropathy: Still the Achilles' Heel of Interventional Cardiology
- Countdown to COMBAT